3ft4 › Citations

Steric hindrance and fast dissociation explain the lack of immunogenicity of the minor histocompatibility HA-1Arg Null allele.

Spierings E, Gras S, Reiser JB, Mommaas B, Almekinders M, Kester MG, Chouquet A, Le Gorrec M, Drijfhout JW, Ossendorp F, Housset D, Goulmy E
J Immunol 182 4809-16 (2009)
Related entries: 3ft2, 3ft3

Cited: 22 times
EuropePMC logo PMID: 19342659

Abstract

The di-allelic HLA-A2 restricted minor histocompatibility Ag HA-1 locus codes for the highly immunogenic HA-1(His) and the nonimmunogenic HA-1(Arg) nonapeptides, differing in one amino acid. The HA-1(His) peptide is currently used for boosting the graft-vs-tumor responses after HLA matched HA-1 mismatched stem cell transplantation; usage of the HA-1(Arg) peptide would significantly enlarge the applicability for this therapy. Our studies on mechanisms causing the HA-1 unidirectional immunogenicity revealed marginal differences in proteasomal digestion, TAP translocation, and binding affinity, whereas both dissociation rates and structural analyses clearly showed marked differences in the stability of these two HLA-A2 bound alleles. These data provide a rationale for the lack of HA-1(Arg) peptide immunogenicity essential for the choice of tumor peptides for stem cell-based immunotherapeutic application.

Articles - 3ft4 mentioned but not cited (2)

  1. Broad TCR repertoire and diverse structural solutions for recognition of an immunodominant CD8+ T cell epitope. Song I, Gil A, Mishra R, Ghersi D, Selin LK, Stern LJ. Nat Struct Mol Biol 24 395-406 (2017)
  2. Predicting HLA class I non-permissive amino acid residues substitutions. Binkowski TA, Marino SR, Joachimiak A. PLoS One 7 e41710 (2012)


Reviews citing this publication (10)

  1. Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia. Bleakley M, Riddell SR. Immunol Cell Biol 89 396-407 (2011)
  2. Minor histocompatibility antigens: past, present, and future. Spierings E. Tissue Antigens 84 374-360 (2014)
  3. Understanding the complexity and malleability of T-cell recognition. Miles JJ, McCluskey J, Rossjohn J, Gras S. Immunol Cell Biol 93 433-441 (2015)
  4. Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation. Bleakley M, Turtle CJ, Riddell SR. Expert Rev Hematol 5 409-425 (2012)
  5. TCR-Like CAR-T Cells Targeting MHC-Bound Minor Histocompatibility Antigens. Akatsuka Y. Front Immunol 11 257 (2020)
  6. Tumor vaccines and beyond. Melenhorst JJ, Barrett AJ. Cytotherapy 13 8-18 (2011)
  7. The Connection Between Minor H Antigens and Neoantigens and the Missing Link in Their Prediction. Mutis T, Xagara A, Spaapen RM. Front Immunol 11 1162 (2020)
  8. TCR Recognition of Peptide-MHC-I: Rule Makers and Breakers. Szeto C, Lobos CA, Nguyen AT, Gras S. Int J Mol Sci 22 (2020)
  9. Minor Histocompatibility Antigen-Specific T Cells. Summers C, Sheth VS, Bleakley M. Front Pediatr 8 284 (2020)
  10. Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery. de Sousa E, Lérias JR, Beltran A, Paraschoudi G, Condeço C, Kamiki J, António PA, Figueiredo N, Carvalho C, Castillo-Martin M, Wang Z, Ligeiro D, Rao M, Maeurer M. Front Immunol 12 592031 (2021)

Articles citing this publication (10)

  1. Peptide-MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity. Harndahl M, Rasmussen M, Roder G, Dalgaard Pedersen I, Sørensen M, Nielsen M, Buus S. Eur J Immunol 42 1405-1416 (2012)
  2. Pan-Specific Prediction of Peptide-MHC Class I Complex Stability, a Correlate of T Cell Immunogenicity. Rasmussen M, Fenoy E, Harndahl M, Kristensen AB, Nielsen IK, Nielsen M, Buus S. J Immunol 197 1517-1524 (2016)
  3. Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse. Dossa RG, Cunningham T, Sommermeyer D, Medina-Rodriguez I, Biernacki MA, Foster K, Bleakley M. Blood 131 108-120 (2018)
  4. Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes. Ofran Y, Kim HT, Brusic V, Blake L, Mandrell M, Wu CJ, Sarantopoulos S, Bellucci R, Keskin DB, Soiffer RJ, Antin JH, Ritz J. Clin Cancer Res 16 1642-1651 (2010)
  5. Letter Thermodynamic characterization of dissociation rate variations of human leukocyte antigen and peptide complexes. Kang J, Auerbach JD. Mol Immunol 46 2873-2875 (2009)
  6. Analysis of relationships between peptide/MHC structural features and naive T cell frequency in humans. Reiser JB, Legoux F, Gras S, Trudel E, Chouquet A, Léger A, Le Gorrec M, Machillot P, Bonneville M, Saulquin X, Housset D. J Immunol 193 5816-5826 (2014)
  7. Possible role of minor h antigens in the persistence of donor chimerism after stem cell transplantation; relevance for sustained leukemia remission. van der Torren CR, van Hensbergen Y, Luther S, Aghai Z, Rychnavská ZS, Slot M, Scherjon S, Kröger N, Ganser A, Weissinger EM, Goulmy E, Hambach L. PLoS One 10 e0119595 (2015)
  8. Specific T Cell Responses against Minor Histocompatibility Antigens Cannot Generally Be Explained by Absence of Their Allelic Counterparts on the Cell Surface. Bijen HM, Hassan C, Kester MGD, Janssen GMC, Hombrink P, de Ru AH, Drijfhout JW, Meiring HD, de Jong AP, Falkenburg JHF, Jimenez CR, Heemskerk MHM, van Veelen PA. Proteomics 18 e1700250 (2018)
  9. The potential HLA Class I-restricted epitopes derived from LeIF and TSA of Leishmania donovani evoke anti-leishmania CD8+ T lymphocyte response. Dikhit MR, Das S, Mahantesh V, Kumar A, Singh AK, Dehury B, Rout AK, Ali V, Sahoo GC, Topno RK, Pandey K, Das VNR, Bimal S, Das P. Sci Rep 8 14175 (2018)
  10. Transgenic HA-1-Specific CD8+ T-Lymphocytes Selectively Target Leukemic Cells. Pilunov A, Romaniuk DS, Shmelev A, Sheetikov S, Gabashvili AN, Khmelevskaya A, Dianov D, Zornikova K, Shakirova NT, Vagida M, Bogolyubova A, Efimov GA. Cancers (Basel) 15 1592 (2023)


Quick links